Cadent Therapeutics — a Cambridge, Mass.-based startup with a complicated history — announced Thursday that it has raised about $40 million for its neuroscience programs in a series B round backed by Atlas Venture, Cowen Healthcare Investments, and Novartis Institutes for BioMedical Research, among others.

Among biotech startups, Cadent is bucking a trend. Lately, entrepreneurs have gravitated toward working on platforms instead of individual potential drugs. In theory, that strategy lessens some of the risk inherent in early-stage biotechs. If a company is based around one particular drug and that drug fails, that could blow up a company’s entire future.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy